The germline/soma dichotomy: implications for aging and degenerative disease

Open Access Review by Michael D West, Francois Binette, David Larocca, Karen B Chapman, Charles Irving & Hal Sternberg discusses potential industrial-scale cell-based regenerative therapies such as transcriptional reprogramming or hESC engineering for the treatment of age-related pathologies.

Go to the profile of Regenerative Medicine
May 11, 2016
0
0
Upvote 0 Comment

Division of human somatic cells results in telomere shortening and subsequently senescence, meaning that the cells are less able to respond to disease or injury, and age-related pathologies may develop. However, pluripotent stem cells cultured in vitro appear to maintain long telomere length owing to relatively high levels of telomerase activity, which the somatic cells lose upon cell division.

In this Open Access Review by Michael D West, Francois Binette, David Larocca, Karen B Chapman, Charles Irving & Hal Sternberg, the authors, from BioTime, Inc., ReCyte Therapeutics and OncoCyte Corporation (all Alameda, CA, USA) discuss the cellular basis of age-related pathology, and pluripotent stem cells as possible therapeutic approaches for the treatment of age-related degenerative diseases.

West MD, Binette F, Larocca D, Chapman KB, Irving C, Sternberg H. The germline/soma dichotomy: implications for aging and degenerative disease. Regen. Med. 11, No. 3, Pages 331-334 (2016). Author for correspondence: mwest@biotimemail.com

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.